The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores
Open accessAbstract
Background: Prediction of thrombotic and bleeding risk is important to optimize antithrombotic therapy after percutaneous coronary intervention. Methods and Results: We developed the prediction rules for thrombotic and bleeding events separately in Japanese patients. Derivation and validation cohorts consisted of 4778 patients from CREDO ‐Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) registry cohort 2 and 4669 patients from RESET (Randomized Evaluation of Sirolimus‐Eluting Versus Everolimus‐Eluting Stent Trial) and NEXT (Nobori Biolimus‐Eluting Versus Xience/Promus Everolimus‐Eluting Stent Trial). Primary thrombotic and bleeding events were a composite of myocardial infarction, definite or probable stent thrombosis or ischemic stroke, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate or severe bleeding. The prediction rule for thrombosis assigned 2 points for severe chronic kidney disease, atrial fibrillation, peripheral vascular disease, and anemia and 1 point for age ≥75 years, heart failure, diabetes mellitus, and chronic total occlusion. The prediction rule for bleeding assigned 2 points for thrombocytopenia, severe chronic kidney disease, peripheral vascular disease, and heart failure and 1 point for prior myocardial infarction, malignancy, and atrial fibrillation. In derivation and validation cohorts, area under the curve was 0.68 and 0.64, respectively, for thrombosis and 0.66 and 0.66, respectively, for bleeding. In the validation cohort, a high thrombosis risk score (≥4, n=682) was associated with higher 3‐year incidence of thrombotic events than a score that was intermediate (2–3, n=1178) or low (0–1, n=2809) (7.6%, 3.7%, versus 2.4%, respectively; P <0.0001). A high bleeding risk score (≥3, n=666) was associated with higher incidence of bleeding than scores that were intermediate (1–2, n=1802) or low (0, n=2201) (8.8%, 4.1%, versus 2.3%, respectively; P <0.0001). Among 682 patients at high thrombotic risk, only 39 (5.7%) had low bleeding risk, whereas 401 (58.8%) had high bleeding risk with very high incidence of bleeding (11.6%). Conclusions: CREDO ‐Kyoto thrombotic and bleeding risk scores demonstrated modest accuracy in stratifying thrombotic and bleeding risks; however, a large proportion of patients at high thrombotic risk also had high bleeding risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928 · cited 1×
“P rolonged duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was shown to significantly reduce the risk of myocardial infarction (MI) and stent thrombosis (ST) compared with aspirin monotherapy in the DAPT (Dual Antiplatelet Therapy) trial.(1) However, prolonged DAPT was also…”
MethodAlba, A. C., Agoritsas, T., Walsh, M., Hanna, S., Iorio, A., Devereaux, P. J., McGinn, T., & Guyatt, G. (2017) · JAMA · doi:10.1001/jama.2017.12126 · Cited by 1,631
Yeh, R. W., Secemsky, E. A., Kereiakes, D. J., Normand, S.-L. T., Gershlick, A. H., Cohen, D. J., Spertus, J. A., Steg, P. G., Cutlip, D. E., Rinaldi, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.3775 · Cited by 934
Bohula, E. A., Bonaca, M. P., Braunwald, E., Aylward, P. E., Corbalan, R., De Ferrari, G. M., He, P., Lewis, B. S., Merlini, P. A., Murphy, S. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019861 · Cited by 168
Cited by
Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 857
Self-citationJCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1109 · Cited by 352
Self-citationWatanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5244 · Cited by 325
Self-citation
Metadata
- Authors
- Natsuaki, M., Morimoto, T., Yamaji, K., Watanabe, H., Yoshikawa, Y., Shiomi, H., Nakagawa, Y., Furukawa, Y., Kadota, K., Ando, K., Akasaka, T., Hanaoka, K. I., Kozuma, K., Tanabe, K., Morino, Y., Muramatsu, T., Kimura, T., & the CREDO‐Kyoto PCI/CABG Registry Cohort 2, R.
- Venue
- Journal of the American Heart Association
- Published
- 2018-06-05
- Volume
- 7
- Issue
- 11
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2804251795
- Cited by
- 195
- References
- 4
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores. https://app.cochat.ai/papers/10.1161/jaha.118.008708
- The paper
- Natsuaki, M., Morimoto, T., Yamaji, K., Watanabe, H., Yoshikawa, Y., Shiomi, H., Nakagawa, Y., Furukawa, Y., Kadota, K., Ando, K., Akasaka, T., Hanaoka, K. I., Kozuma, K., Tanabe, K., Morino, Y., Muramatsu, T., Kimura, T., & the CREDO‐Kyoto PCI/CABG Registry Cohort 2, R. (2018). Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores. Journal of the American Heart Association. https://doi.org/10.1161/jaha.118.008708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.